Clinical outcome of ET-743 (trabectedin; Yondelis) in high-grade uterine sarcomas: Report on five patients and a review of the literature

International Journal of Gynecological Cancer

Volumn 19, Issue 2, 2009, Pages 245-248

  Amant, Frédéric ^a,d   Coosemans, An ^a   Renard, Vincent ^b   Everaert, Els ^c   Vergote, Ignace ^a  

^a Katholieke Universiteit   (Belgium)

^b Department of Medical Oncology

^c AZ Nikolaas   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

ET 743; Leiomyosarcoma; Sarcoma; Trabectedin; Uterine; Yondelis

Indexed keywords

TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; HUMAN; LEIOMYOSARCOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS SARCOMA; CASE REPORT; MIDDLE AGED; REVIEW; SARCOMA; UTERUS CANCER;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; FEMALE; HUMANS; MIDDLE AGED; SARCOMA; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 65649116202     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819c0f59     Document Type: Article

References (13)

1. Yovine A, Riofrio M, Blay J, et al. Phase II study of Ectaneiscidin-743 in advanced soft tissue sarcoma patients. J Clin Oncol. 2004;22: 890-899.
2. Garcia-Carbonero R, Supko J, Maki R, et al. Ectaneiscidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484-5492.
3. Le Cesne A, Blay J, Judson I, et al. Phase II study of ET-743 in advanced soft-tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft-tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576-584.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
5. Amant F, Woestenborghs H, Vandenbroucke V, et al. Transition of endometrial stromal sarcoma into high grade sarcoma. Gynecol Oncol. 2006;103:1137-1140.
6. Tewari D, Saffari B, Cowan C, et al. Activity of trabectin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma. Gynecol Oncol. 2006;102:421-424.
7. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ectaneiscidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumors. Eur J Cancer. 2003;39:1842-1851.
8. Omura G, Major F, Blessing J, et al. A randomized study of adriamycin with and without dimethyl triazinoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626-632.
9. Lissoni A, Cormio G, Colombo N, et al. High-dose epirubicin in patients with advanced or recurrent uterine sarcoma. Int J Gynecol Cancer. 1997;7:241-244.
10. Sutton G, Blessing J, Barrett R, et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1992;166:556-559.
11. Hensley M, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831.
12. Bay O, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006;119:706-711.
13. Maki R, Wathen J, Patel S, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755-2763.